503A vs 503B: choosing a compounding pharmacy for your GLP-1 and peptide program
Every compounded program lives or dies on its pharmacy partners. The 503A/503B distinction decides what they can make, how they can ship it, and how much of your compliance story they carry for you.
Lithos Staff503A pharmacies compound patient-specific prescriptions under state board oversight and can serve a telehealth program in every state where they hold a non-resident license. 503B outsourcing facilities are FDA-registered, follow cGMP, and may produce larger batches — but with a narrower list of what they can make and different rules on when a prescription is needed. Most telehealth programs run on a bench of two to four 503A pharmacies chosen for licensure coverage, turnaround, and documentation quality, adding 503B supply where the product and the rules fit. Vet both on licenses, testing, sourcing, and audit trail before the first order.
Two pharmacies, two rulebooks
Both kinds of compounding pharmacy sit under Section 503 of the federal Food, Drug, and Cosmetic Act, and the section letter is the whole distinction. A 503A pharmacy is the traditional model: a licensed pharmacist compounds a preparation for a specific patient in response to a valid prescription, under the oversight of the state board of pharmacy. A 503B outsourcing facility is a category created by the 2013 Drug Quality and Security Act: it registers with the FDA, follows cGMP the way a manufacturer does, submits to FDA inspection, and in exchange may compound larger batches, including for office administration where state law permits.
For a telehealth program dispensing compounded GLP-1s, peptides, or hormones, the practical differences are what each can make, how a prescription flows to it, and how much of your quality and compliance story it can carry for you.
Side by side
| 503A pharmacy | 503B outsourcing facility | |
|---|---|---|
| Primary regulator | State board of pharmacy (FDA has authority but state leads) | FDA, with state licensure on top |
| Quality standard | USP chapters (795, 797, 800) | cGMP, the manufacturer standard |
| Prescription | Patient-specific, required before compounding (limited anticipatory compounding allowed) | Patient-specific or office-use batches, depending on state rules |
| Batch size | Small; tied to prescriptions on hand | Larger; production-scale |
| What it may compound | Broad, subject to FDA bulk lists and copy restrictions | Narrower; the FDA 503B bulks list and shortage rules govern |
| Testing and stability data | Varies widely by pharmacy; ask for it | Lot-level release testing is the norm |
| Typical role in a program | Core dispensing partner, 50-state via non-resident licenses | High-volume or sterile supply where the product fits the rules |
How well-run programs use both
The strongest programs we see do not pick one. They build a bench: two to four 503A pharmacies selected so that every state the program serves is covered by at least two licensed pharmacies, with prescriptions routed by state, product, and turnaround. Where a product and the current rules allow, a 503B facility adds supply that comes with lot-level testing and manufacturer-grade documentation, which is a genuine asset when you are describing your quality story to patients, partners, and regulators.
The patient-specific pathway is the foundation and it is a legitimate, durable practice. What separates programs that grow from programs that stall is the discipline around it: a clinician documenting the clinical rationale for the compounded preparation, a pharmacy with the license to fill it, and a record that ties the two together for every order. Get the routing and the documentation right and the pharmacy bench becomes a growth lever rather than a constraint.
The vetting checklist
- Licensure map. Home-state license plus a non-resident pharmacy license in every state you ship into. Spot-check three against the boards yourself.
- Sterile permits and accreditation. For injectables, sterile compounding permits and, ideally, PCAB or equivalent accreditation.
- Source of API. Bulk substances from FDA-registered suppliers, with certificates of analysis you can inspect. This is the single most common gap.
- Testing. Potency, sterility, and endotoxin testing cadence; beyond-use dating supported by stability data, not defaults.
- Turnaround and shipping. Cold-chain capability, carrier coverage by region, and real median time from order to delivery.
- Integration. Can prescriptions arrive electronically (NCPDP SCRIPT or API), with status webhooks back? Faxed orders do not scale.
- Audit trail. Can they produce the order, the prescription, the lot, and the shipment record for any patient on request?
- Marketing posture. Pharmacies that make product claims on their own sites create exposure for the programs they supply. Read their homepage like a regulator would.
Red flags
- Will ship to a state where they cannot show a license.
- Cannot name the API supplier or produce a certificate of analysis.
- Offers to compound “research” product without a prescription.
- Pricing that only makes sense if testing is being skipped.
Frequently asked questions
What is the difference between a 503A and a 503B pharmacy?
503A pharmacies compound individual prescriptions for identified patients and are regulated mainly by state boards of pharmacy. 503B outsourcing facilities register with the FDA, follow current good manufacturing practice (cGMP), and can compound in larger quantities, including for office use where state law allows. Both operate under Section 503 of the Food, Drug, and Cosmetic Act.
Can a 503B facility make compounded semaglutide or tirzepatide?
Only within the rules that apply at the time: what a 503B may compound depends on the FDA’s bulk-substance lists, shortage status, and whether the product is essentially a copy of an approved drug. Check the current position for each molecule with the facility and with counsel rather than assuming.
How many compounding pharmacies should a telehealth program use?
Enough that no single state or product depends on one pharmacy — usually two to four. Redundancy covers licensure gaps, capacity crunches, and shipping regions, and it lets you route each prescription to the best-fit pharmacy automatically.
What licenses does a compounding pharmacy need to ship to my patients?
A home-state pharmacy license plus a non-resident pharmacy license (or equivalent registration) in every state it ships into. Sterile compounding usually needs additional permits. Ask for the license list and verify a sample against the state boards.
From first call to first patient, in weeks.
A 15-minute intro call, sandbox credentials the same day, go-live in 3–4 weeks — new launches and existing patient bases alike.